Treatment with the combination of the CD40 agonist mitazalimab and modified FOLFIRINOX (oxaliplatin, leucovorin, irinotecan, and fluorouracil; mFOLFIRINOX) generated potentially favorable overall survival (OS) outcomes compared with historical…
Mitazalimab Plus Chemo Demonstrates Potential OS Benefit in Previously Untreated Metastatic Pancreatic Cancer
